Citigroup Inc. lowered its position in Integer Holdings Co. (NYSE:ITGR - Free Report) by 99.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 78,181 shares of the medical equipment provider's stock after selling 7,744,094 shares during the quarter. Citigroup Inc. owned 0.23% of Integer worth $10,164,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently added to or reduced their stakes in the company. Driehaus Capital Management LLC increased its position in shares of Integer by 62.5% in the second quarter. Driehaus Capital Management LLC now owns 353,052 shares of the medical equipment provider's stock worth $40,880,000 after acquiring an additional 135,750 shares in the last quarter. Eagle Asset Management Inc. purchased a new stake in Integer during the 3rd quarter worth $14,403,000. F M Investments LLC acquired a new stake in Integer in the 2nd quarter valued at $11,143,000. Point72 Europe London LLP purchased a new position in Integer in the second quarter valued at about $6,241,000. Finally, Earnest Partners LLC lifted its stake in shares of Integer by 3.2% during the second quarter. Earnest Partners LLC now owns 1,208,319 shares of the medical equipment provider's stock worth $139,911,000 after purchasing an additional 37,340 shares in the last quarter. Hedge funds and other institutional investors own 99.29% of the company's stock.
Integer Trading Down 0.1 %
NYSE ITGR opened at $140.71 on Friday. The company's fifty day moving average price is $131.38 and its two-hundred day moving average price is $124.36. The company has a market capitalization of $4.72 billion, a price-to-earnings ratio of 43.43, a price-to-earnings-growth ratio of 2.02 and a beta of 1.09. Integer Holdings Co. has a 12 month low of $84.75 and a 12 month high of $142.00. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.28 and a quick ratio of 2.09.
Integer (NYSE:ITGR - Get Free Report) last posted its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 EPS for the quarter, topping analysts' consensus estimates of $1.36 by $0.07. Integer had a return on equity of 11.63% and a net margin of 6.70%. The business had revenue of $431.42 million during the quarter, compared to the consensus estimate of $440.59 million. During the same period last year, the firm earned $1.27 earnings per share. The company's revenue for the quarter was up 8.7% compared to the same quarter last year. As a group, research analysts predict that Integer Holdings Co. will post 5.34 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on ITGR shares. Bank of America raised their target price on Integer from $135.00 to $145.00 and gave the company a "buy" rating in a report on Tuesday, October 1st. Citigroup lifted their price objective on shares of Integer from $124.00 to $130.00 and gave the company a "neutral" rating in a research note on Tuesday, October 1st. KeyCorp upped their target price on shares of Integer from $139.00 to $144.00 and gave the company an "overweight" rating in a research note on Tuesday, October 15th. Piper Sandler reaffirmed an "overweight" rating and set a $140.00 price target (up previously from $125.00) on shares of Integer in a research note on Friday, October 25th. Finally, Benchmark upped their price objective on shares of Integer from $130.00 to $140.00 and gave the company a "buy" rating in a research report on Monday, October 21st. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Integer has an average rating of "Moderate Buy" and an average target price of $139.75.
Get Our Latest Analysis on Integer
About Integer
(
Free Report)
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.
Featured Articles
Before you consider Integer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integer wasn't on the list.
While Integer currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.